NICE has developed medical technology guidance on th ReCell Spray-On Skin system.
NICE medical technologies guidance addresses specific technologies notified to NICE by sponsors. The 'case for adoption' is based on the claimed advantages of introducing the specific technology compared with current management of the condition. This case is reviewed against the evidence submitted and expert advice. The medical technology guidance on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury recommends further research. This recommendation is not intended to preclude the use of the technology in the NHS but to identify further evidence which, after evaluation, could support a recommendation for wider adoption.
NICE has said that the ReCell Spray-On Skin system shows potential to improve healing in acute burns. Research is recommended to address uncertainties about the claimed patient and system benefits of the ReCell Spray-On Skin system.